What These 4 DocuSign Analysts Have To Say About Q4 Print
Shares of DocuSign Inc (NASDAQ: DOCU) fell in the premarket on Friday, even after the company reported better-than-expected fourth-quarter earnings.
Wedbush Reiterates Outperform on Elevation Oncology, Maintains $4 Price Target
Wedbush analyst Robert Driscoll reiterates Elevation Oncology (NASDAQ:ELEV) with a Outperform and maintains $4 price target.
Wedbush Reiterates Outperform on Surface Oncology, Maintains $3 Price Target
Wedbush analyst Robert Driscoll reiterates Surface Oncology (NASDAQ:SURF) with a Outperform and maintains $3 price target.
Benchmark Reiterates Buy on Tenon Medical, Maintains $6 Price Target
Benchmark analyst Jackson Ader reiterates Tenon Medical (NASDAQ:TNON) with a Buy and maintains $6 price target.
Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target
Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.
Benchmark Reiterates Buy on Archer Aviation, Maintains $12 Price Target
Benchmark analyst Josh Sullivan reiterates Archer Aviation (NYSE:ACHR) with a Buy and maintains $12 price target.
Benchmark Reiterates Buy on Getty Images Holdings, Maintains $9 Price Target
Benchmark analyst Mark Zgutowicz reiterates Getty Images Holdings (NYSE:GETY) with a Buy and maintains $9 price target.
Benchmark Reiterates Buy on JD.com, Maintains $76 Price Target
Benchmark analyst Fawne Jiang reiterates JD.com (NASDAQ:JD) with a Buy and maintains $76 price target.
Stephens & Co. Reiterates Equal-Weight on Yellow, Maintains $3 Price Target
Stephens & Co. analyst Jack Atkins reiterates Yellow (NASDAQ:YELL) with a Equal-Weight and maintains $3 price target.
Cantor Fitzgerald Reiterates Overweight on Enovix, Maintains $25 Price Target
Cantor Fitzgerald analyst Derek Soderberg reiterates Enovix (NASDAQ:ENVX) with a Overweight and maintains $25 price target.